Education
About Us
Working with TipRanks
Follow Us
Arrowhead Pharmaceuticals (ARWR)
NASDAQ:ARWR
Earnings Data
Report Date
Aug 11, 2025TBA Not Confirmed
Period Ending
2025 (Q3)Consensus EPS Forecast
-0.95Last Year’s EPS
-1.38Same Quarter Last Year
Moderate Buy
Based on 11 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 12, 2025
|% Change Since: 16.11%
|Next Earnings Date:Aug 11, 2025
Earnings Call Sentiment|Positive
Arrowhead Pharmaceuticals demonstrated strong financial performance and significant progress in its pipeline, particularly with the upcoming launch of Plozasiran and promising data from clinical trials. However, the company faces regulatory uncertainties and market challenges, with a heavy reliance on partnerships for future revenue. The sentiment is generally positive due to the outweighing highlights.Company Guidance
During the Arrow Pharmaceuticals Conference Call, management provided a comprehensive update on the company's progress and future plans. The key highlight was the anticipated commercial launch of plozasiran, a potent triglyceride-lowering agent, later this year, pending regulatory approval. The PDUFA date is set for November 18, 2025, with a Marketing Authorization Application (MAA) submitted to the EMA. Phase III data showed impressive triglyceride reductions of about 80%, with 75% and 50% of patients achieving triglyceride levels below 880 and 500 milligrams per deciliter, respectively. Arrowhead plans to expand into the broader severe hypertriglyceridemia (SHTG) market, with ongoing SHASTA-3, SHASTA-4, and MUIR 3 studies expected to complete enrollment this summer. The company is also advancing its obesity candidates, ARO-INHBE and ARO-ALK7, with initial data expected by the end of 2025. Arrowhead's CNS platform is progressing, with the first candidate targeting the Tau protein for Alzheimer's disease expected to enter the clinic late this year. Financially, the company is strong, with $1.1 billion in cash and investments and a recent deal with Sarepta Therapeutics contributing $825 million in upfront payments and equity investment, supporting operations into 2028.Strong Financial Performance
Arrowhead reported a net income of $370.4 million for the quarter ended March 31, 2025, compared to a net loss of $125.3 million in the same period of 2024. Revenue for the quarter was $542.7 million, primarily due to the license and collaboration agreement with Sarepta.
Upcoming Launch of Plozasiran
Arrowhead is preparing for the commercial launch of Plozasiran for Familial Chylomicronemia Syndrome (FCS), with a PDUFA date set for November 18, 2025. The company is building its commercial sales team and engaging with payers in anticipation of launch.
Advanced Pipeline and Partnerships
The company highlighted its advanced pipeline with multiple Phase III programs, including SHASTA-3, SHASTA-4, and MUIR-3 for severe hypertriglyceridemia (SHTG) and partnerships with Sarepta and Takeda. The Sarepta deal brought in $500 million upfront and potential milestones exceeding $11 billion.
Encouraging Clinical Data
Plozasiran showed reductions in triglycerides by about 80% from baseline in Phase III studies. The company is also seeing progress with obesity candidates ARO-INHBE and ARO-ALK7, with expected initial data by the end of 2025.
ARWR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ARWR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 12, 2025 | $13.97 | $15.28 | +9.38% |
Feb 10, 2025 | $19.92 | $18.89 | -5.17% |
Nov 26, 2024 | $21.05 | $26.15 | +24.23% |
Aug 08, 2024 | $25.85 | $23.41 | -9.44% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Arrowhead Pharmaceuticals (ARWR) report earnings?
Arrowhead Pharmaceuticals (ARWR) is schdueled to report earning on Aug 11, 2025, TBA Not Confirmed.
What is Arrowhead Pharmaceuticals (ARWR) earnings time?
Arrowhead Pharmaceuticals (ARWR) earnings time is at Aug 11, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ARWR EPS forecast?
ARWR EPS forecast for the fiscal quarter 2025 (Q3) is -0.95.